| MINERVA NEUROSCIENCES |
| USA |
| Gesundheit |
| US6033802058 / A3DMH5 |
| 4MNA (Frankfurt) / NERV (NASDAQ) |
| FRA:4MNA, ETR:4MNA, 4MNA:GR, NASDAQ:NERV |
| - |
| https://www.minervaneuros.. |
|
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negati..
>Volltext.. |
| 182.15 Mio. EUR |
| 179.03 Mio. EUR |
| - |
| -30.26 Mio. EUR |
| -339.6 Mio. EUR |
| -24.44 EUR |
| 61.78 Mio. EUR |
| 21.32 Mio. EUR |
| -22.54 Mio. EUR |
| 19.04 |
| - |
| -3611.7% |
| - |
| - |
| - |
| - |
| MINERVA NEUROSCIENCES, MINERVA NEURO, MINERVA NEUROSCIENCE |
| 10.09.26 |
|